ScreenerHero

ORMP Oramed Pharmaceuticals Inc.

NAS · US · Healthcare · Biotechnology · oramed.com
4.370USD-0.23%Mkt Cap: 178.85M $P/E: 1.06

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, wh…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap178.85M USD
Enterprise Value132.32M USD
Revenue (TTM)0 USD
Gross Profit13.00K USD
Net Income (TTM)64.05M USD
Revenue/Share0.00 USD
Last Price4.370 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)1.06
P/E (Forward)-54.75
PEG—
EV/EBITDA-9.19
EV/Revenue—
P/SInfinity
P/B0.57
EPS (TTM)3.99
EPS (Forward)-0.08
52W Range
2.09068% of range5.430
52W High5.430 USD
52W Low2.090 USD
Profitability
Gross Margin0.65%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin3202.50%
ROE32.07%
ROA27.74%
Growth
Revenue Growth—
Earnings Growth493.50%
Cash Flow & Leverage
Operating CF-9.14M USD
CapEx (TTM)1.93M USD
FCF Margin—
FCF Yield1.40%
Net Debt-49.88M USD
Net Debt/EBITDA3.46
Balance Sheet
Debt/Equity0.00
Current Ratio4.98
Quick Ratio4.85
Book Value/Sh7.68 USD
Cash/Share1.22 USD
Dividends
Fwd Div Rate0.25 USD
Trail. Div Rate0.00 USD
Div. Yield5.51%
5Y Avg Yield—
Payout Ratio6.05%
Ex-Div DateJan 16, 2026
Pay DateJan 26, 2026
Splits
Last Split1:12
Split DateJan 23, 2013
Analyst Consensus
Rating—
Target (Mean)7.000 USD
Upside (mean)+60.2%
Target Range7.000 USD – 7.000 USD
# Analysts1
Ownership
Shares Out.40.93M
Float29.83M
Insiders21.27%
Institutions45.14%
Short Interest
Short Ratio5.8d
Short % Float3.80%
Short % Out.3.14%
Shares Short1.31M
Short (prev mo.)1.03M
Technical
SMA 504.640 (-5.8%)
SMA 2003.937 (+11.0%)
Beta1.28
S&P 52W Chg16.45%
Avg Vol (30d)194.12K
Avg Vol (10d)152.35K
Technical Indicators
RSI (14)38.9
MACD-0.0449
MACD Signal0.0122
MACD Hist.-0.0571
BB Upper5.013 USD
BB Middle4.679 USD
BB Lower4.346 USD
BB Width14.25%
ATR (14)0.1776 USD
Vol Ratio (20d)0.45x